StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) KPIs and segments

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)

Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của AbbVie · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của AbbVie: 58 chỉ số vận hành, trong đó có Total Net Revenues — Worldwide, Net Revenues by Country và Long-Lived Assets by Geographic Region, lấy từ 126 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1
Total Net Revenues — Worldwide ($M)($M)4
16,99015,00216,61815,77615,42313,34315,10214,46014,46212,31014,30113,927
Total Net Revenues — United States ($M)($M)1
12,86110,96912,79412,06811,7629,97911,73411,14811,1069,04111,11010,852
United States — Reported revenue growth YoY (%)(%)
9.3%9.9%9.0%8.2%5.9%10.4%5.6%2.7%3.6%-1.7%-8.9%-7.7%
Total Net Revenues — International ($M)($M)2
4,1294,0333,8243,7083,6613,3643,3683,3123,3563,2693,1913,075
International — Reported revenue growth YoY (%)(%)
12.8%19.9%13.5%12.0%9.1%2.9%5.6%7.7%6.8%8.1%8.9%0.8%
International — Operational (constant-currency) revenue growth YoY (%)(%)
10.2%11.4%11.0%9.0%8.4%8.3%7.8%12.4%12.7%11.6%9.0%1.4%
Worldwide — Reported revenue growth YoY (%)(%)
10.2%12.4%10.0%9.1%6.6%8.4%5.6%3.8%4.3%0.7%-5.4%-6.0%
Worldwide — Operational (constant-currency) revenue growth YoY (%)(%)
9.5%10.3%9.5%8.4%6.5%9.8%6.1%4.9%5.6%1.6%-5.4%-5.8%
Immunology Portfolio — Worldwide net revenues ($M)($M)7
8,7867,2908,6267,8857,6316,2647,2947,0466,9715,3716,9536,783
Immunology Portfolio — U.S. net revenues ($M)($M)1
6,9575,5376,9616,2636,0974,8835,9055,7135,7174,1525,7745,696
Immunology Portfolio — U.S. reported growth YoY (%)(%)
14.1%13.4%17.9%9.6%6.7%17.6%2.2%0.3%-0.2%-8.5%-17.2%-14.7%
Immunology Portfolio — International net revenues ($M)($M)2
1,8291,7531,6651,6221,5341,3811,3891,3331,2541,2191,1791,087
Immunology Portfolio — International reported growth YoY (%)(%)
19.2%26.9%19.7%21.7%22.3%13.4%17.8%22.7%15.9%16.0%24.3%12.1%
Immunology Portfolio — International operational (constant-currency) growth YoY (%)(%)
16.8%17.3%16.8%17.9%20.7%20.1%20.2%28.4%23.5%20.5%24.0%11.9%
Immunology Portfolio — Worldwide reported growth YoY (%)(%)
15.1%16.4%18.3%11.9%9.5%16.6%4.9%3.9%2.3%-3.9%-12.3%-11.3%
Immunology Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)
14.6%14.3%17.7%11.2%9.2%18.1%5.3%4.8%3.5%-3.1%-12.3%-11.3%
Skyrizi (risankizumab) — Worldwide net revenues ($M)($M)4
5,5054,4835,0064,7084,4233,4253,7783,2052,7272,0082,3942,126
Skyrizi (risankizumab) — U.S. net revenues ($M)($M)1
4,7673,7754,3554,0853,8432,9193,3122,7782,3401,6562,1051,875
Skyrizi (risankizumab) — U.S. reported growth YoY (%)(%)
24.0%29.3%31.5%47.0%64.3%76.2%57.3%48.3%43.2%45.3%50.0%53.5%
Skyrizi (risankizumab) — International net revenues ($M)($M)2
738708651623580506466427387352289251
Skyrizi (risankizumab) — International reported growth YoY (%)(%)
27.3%39.8%39.8%45.9%49.7%43.9%61.1%70.0%55.5%59.4%67.5%42.5%
Skyrizi (risankizumab) — International operational (constant-currency) growth YoY (%)(%)
24.2%28.0%35.1%40.2%47.2%52.3%62.4%75.7%61.8%61.6%64.4%40.7%
Skyrizi (risankizumab) — Worldwide reported growth YoY (%)(%)
24.4%30.9%32.5%46.8%62.2%70.5%57.7%50.8%44.8%47.6%51.9%52.1%
Skyrizi (risankizumab) — Worldwide operational (constant-currency) growth YoY (%)(%)
24.0%29.2%31.9%46.0%61.8%72.0%57.9%51.5%45.6%48.0%51.6%51.9%
Rinvoq (upadacitinib) — Worldwide net revenues ($M)($M)4
2,5252,1192,3742,1842,0281,7181,8341,6141,4301,0931,2551,110
Rinvoq (upadacitinib) — U.S. net revenues ($M)($M)1
1,7651,4051,7091,5591,4521,2201,3471,1701,017725929801
Rinvoq (upadacitinib) — U.S. reported growth YoY (%)(%)
21.6%15.1%26.9%33.3%42.7%68.3%45.0%45.9%57.9%61.4%63.9%59.0%
Rinvoq (upadacitinib) — International net revenues ($M)($M)2
760714665625576498487444413368326309
Rinvoq (upadacitinib) — International reported growth YoY (%)(%)
31.9%43.4%36.4%40.7%39.6%35.3%49.5%44.0%51.1%55.3%60.2%61.8%
Rinvoq (upadacitinib) — International operational (constant-currency) growth YoY (%)(%)
29.2%32.6%33.2%36.5%37.5%42.8%53.1%51.6%62.6%62.8%59.8%61.2%
Rinvoq (upadacitinib) — Worldwide reported growth YoY (%)(%)
24.5%23.3%29.5%35.3%41.8%57.2%46.2%45.3%55.8%59.3%62.9%59.8%
Rinvoq (upadacitinib) — Worldwide operational (constant-currency) growth YoY (%)(%)
23.7%20.2%28.6%34.1%41.2%59.7%47.1%47.4%59.2%61.9%62.8%59.6%
Humira (adalimumab) — Worldwide net revenues ($M)($M)4
7566881,2469931,1801,1211,6822,2272,8142,2703,3043,547
Humira (adalimumab) — U.S. net revenues ($M)($M)1
4253578976198027441,2461,7652,3601,7712,7403,020
Humira (adalimumab) — U.S. reported growth YoY (%)(%)
-47.0%-52.0%-27.9%-65.0%-66.0%-58.0%-54.5%-41.6%-31.6%-39.9%-45.3%-39.1%
Humira (adalimumab) — International net revenues ($M)($M)2
331331349374378377436462454499564527
Humira (adalimumab) — International reported growth YoY (%)(%)
-12.5%-12.3%-20.3%-18.9%-16.8%-24.4%-22.7%-12.4%-18.9%-15.8%-1.5%-12.6%
Humira (adalimumab) — International operational (constant-currency) growth YoY (%)(%)
-13.2%-17.4%-21.0%-20.5%-17.2%-19.5%-20.5%-7.8%-12.5%-11.6%-1.0%-12.2%
Humira (adalimumab) — Worldwide reported growth YoY (%)(%)
-35.9%-38.6%-25.9%-55.4%-58.1%-50.6%-49.1%-37.2%-29.8%-35.9%-40.8%-36.2%
Humira (adalimumab) — Worldwide operational (constant-currency) growth YoY (%)(%)
-36.1%-40.3%-26.1%-55.7%-58.2%-49.5%-48.7%-36.5%-28.9%-35.2%-40.7%-36.2%
Neuroscience Portfolio — Worldwide net revenues ($M)($M)11
3,2282,8752,9612,8412,6832,2822,5092,3632,1621,9652,0942,043
Neuroscience Portfolio — U.S. net revenues ($M)($M)1
2,7712,4592,5722,4632,3331,9722,2102,0881,8951,7141,8611,817
Neuroscience Portfolio — U.S. reported growth YoY (%)(%)
18.8%24.7%16.3%18.0%23.2%15.0%18.8%14.9%14.9%17.1%23.7%24.0%
Neuroscience Portfolio — International net revenues ($M)($M)2
457416389378350310299275267251233226
Neuroscience Portfolio — International reported growth YoY (%)(%)
29.9%34.4%30.3%37.2%30.6%24.0%28.4%21.2%13.5%7.9%14.7%8.9%
Neuroscience Portfolio — International operational (constant-currency) growth YoY (%)(%)
25.7%21.8%25.6%32.3%28.7%31.0%29.3%25.1%17.3%8.9%13.0%8.4%
Neuroscience Portfolio — Worldwide reported growth YoY (%)(%)
20.3%26.0%17.9%20.2%24.2%16.1%19.8%15.6%14.7%15.9%22.6%22.1%
Neuroscience Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)
19.8%24.3%17.3%19.6%24.0%17.0%19.9%16.0%15.2%16.0%22.4%22.0%
Vraylar (cariprazine) — Worldwide net revenues ($M)($M)4
1,0719051,022934900765924875774694789751
Vraylar (cariprazine) — U.S. net revenues ($M)($M)1
1,0689021,020931898763922873773692788750
Vraylar (cariprazine) — U.S. reported growth YoY (%)(%)
18.9%18.2%10.5%6.7%16.2%10.3%17.1%16.5%17.5%23.5%39.6%35.2%
Vraylar (cariprazine) — International net revenues ($M)($M)2
332322221211
Vraylar (cariprazine) — International reported growth YoY (%)(%)
30.1%67.6%21.7%31.5%72.8%13.1%25.8%49.3%68.8%
Vraylar (cariprazine) — International operational (constant-currency) growth YoY (%)(%)
28.5%58.9%24.5%32.3%76.8%20.2%26.4%51.9%69.2%
Vraylar (cariprazine) — Worldwide reported growth YoY (%)(%)
18.9%18.4%10.5%6.7%16.3%10.3%17.1%16.6%17.6%23.6%39.8%35.4%
Vraylar (cariprazine) — Worldwide operational (constant-currency) growth YoY (%)(%)
18.9%18.4%10.5%6.7%16.3%10.3%17.1%16.6%17.6%23.6%39.8%35.4%
Botox Therapeutic (onabotulinumtoxinA) — Worldwide net revenues ($M)($M)4
1,0421,009990985928866873848814748776748
Botox Therapeutic (onabotulinumtoxinA) — U.S. net revenues ($M)($M)1
864842828825775723730708669611649626
Botox Therapeutic (onabotulinumtoxinA) — U.S. reported growth YoY (%)(%)
11.4%16.5%13.5%16.6%15.9%18.2%12.4%13.1%8.9%4.1%5.7%7.2%
Botox Therapeutic (onabotulinumtoxinA) — International net revenues ($M)($M)2
178167162160153143143140145137127122
Botox Therapeutic (onabotulinumtoxinA) — International reported growth YoY (%)(%)
16.2%16.3%13.1%13.4%5.7%4.8%13.2%14.6%7.9%3.9%11.5%6.5%
Botox Therapeutic (onabotulinumtoxinA) — International operational (constant-currency) growth YoY (%)(%)
12.5%6.7%10.7%11.3%6.0%11.4%16.3%20.7%13.0%6.3%11.9%8.6%
Botox Therapeutic (onabotulinumtoxinA) — Worldwide reported growth YoY (%)(%)
12.2%16.5%13.4%16.1%14.1%15.8%12.5%13.4%8.7%4.1%6.6%7.1%
Botox Therapeutic (onabotulinumtoxinA) — Worldwide operational (constant-currency) growth YoY (%)(%)
11.6%14.9%13.0%15.8%14.2%17.0%13.0%14.4%9.6%4.5%6.7%7.4%
Ubrelvy (ubrogepant) — Worldwide net revenues ($M)($M)4
392339339354338240303269231203234233
Ubrelvy (ubrogepant) — U.S. net revenues ($M)($M)1
379330332344330233296261227197229230
Ubrelvy (ubrogepant) — U.S. reported growth YoY (%)(%)
15.0%41.7%12.3%31.4%46.5%17.6%28.9%13.6%16.6%31.5%16.9%43.7%
Ubrelvy (ubrogepant) — International net revenues ($M)($M)2
13971087784653
Ubrelvy (ubrogepant) — International reported growth YoY (%)(%)
54.9%29.2%-3.7%34.1%73.9%23.3%65.3%81.6%
Ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%)(%)
52.5%22.9%-3.0%34.2%76.7%29.3%66.2%82.3%
Ubrelvy (ubrogepant) — Worldwide reported growth YoY (%)(%)
16.0%41.4%12.0%31.5%47.1%17.8%29.6%15.3%17.5%33.8%18.9%45.6%
Ubrelvy (ubrogepant) — Worldwide operational (constant-currency) growth YoY (%)(%)
15.9%41.2%12.0%31.5%47.2%18.0%29.6%15.3%17.5%33.8%18.9%45.6%
Qulipta (atogepant) — Worldwide net revenues ($M)($M)4
350296288288267193201176150131114132
Qulipta (atogepant) — U.S. net revenues ($M)($M)1
289250245252237172186168146128113131
Qulipta (atogepant) — U.S. reported growth YoY (%)(%)
22.1%45.4%30.9%50.2%62.8%34.2%65.7%28.3%52.8%94.5%
Qulipta (atogepant) — International net revenues ($M)($M)
6146433630211584311
Qulipta (atogepant) — Worldwide reported growth YoY (%)(%)
30.9%53.6%42.6%64.1%77.5%47.6%76.4%33.6%56.3%97.7%
Qulipta (atogepant) — Worldwide operational (constant-currency) growth YoY (%)(%)
30.3%51.3%41.8%63.1%76.9%48.3%76.2%33.6%56.3%97.7%
Vyalev (foscarbidopa/foslevodopa) — Worldwide net revenues ($M)($M)2
25620118313898634428189
Vyalev (foscarbidopa/foslevodopa) — U.S. net revenues ($M)($M)
1288986532261000
Vyalev (foscarbidopa/foslevodopa) — International net revenues ($M)($M)
128112978576574328189
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide net revenues ($M)($M)4
92969796108111113115115118
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M)($M)1
17162020242423252325
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. reported growth YoY (%)(%)
-31.6%-29.9%-13.6%-19.4%2.8%-4.7%-2.6%-2.6%3.8%10.6%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International net revenues ($M)($M)2
75807776848790909293
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International reported growth YoY (%)(%)
-10.4%-9.0%-13.7%-16.0%-8.1%-7.1%-3.2%-2.7%9.0%6.6%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — International operational (constant-currency) growth YoY (%)(%)
-14.9%-13.8%-16.3%-11.7%-9.7%-6.4%-1.7%-3.7%4.2%2.3%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide reported growth YoY (%)(%)
-15.1%-13.5%-13.7%-16.7%-5.8%-6.6%-3.1%-2.7%7.9%7.4%
Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)(%)
-18.6%-17.3%-15.7%-13.3%-7.0%-6.0%-1.9%-3.5%4.1%4.0%
Other Neuroscience — Worldwide net revenues ($M)($M)4
1171254746152155565662656361
Other Neuroscience — U.S. net revenues ($M)($M)1
434644427175515457615955
Other Neuroscience — U.S. reported growth YoY (%)(%)
-38.6%-38.9%-13.9%-21.7%-11.4%-9.5%-11.7%-4.1%-10.1%-18.5%4.2%-31.9%
Other Neuroscience — International net revenues ($M)($M)2
7479348180525446
Other Neuroscience — International reported growth YoY (%)(%)
-8.9%-1.5%-20.1%92.3%-23.3%-1.0%61.7%6.2%
Other Neuroscience — International operational (constant-currency) growth YoY (%)(%)
-12.4%-11.7%-19.0%94.0%-21.3%6.5%62.5%9.6%
Other Neuroscience — Worldwide reported growth YoY (%)(%)
-22.7%-19.6%-14.4%-17.3%-12.3%-8.9%50.9%36.4%16.6%-6.9%8.5%-29.9%
Other Neuroscience — Worldwide operational (constant-currency) growth YoY (%)(%)
-24.6%-24.8%-14.3%-17.2%-12.2%-8.4%50.4%37.1%17.5%-6.7%8.6%-29.7%
Oncology Portfolio — Worldwide net revenues ($M)($M)9
1,6501,6311,6641,6821,6761,6331,6911,6871,6341,5431,5091,512
Oncology Portfolio — U.S. net revenues ($M)($M)1
9368829971,0301,0261,0271,1021,1131,037967971973
Oncology Portfolio — U.S. reported growth YoY (%)(%)
-8.7%-14.1%-9.6%-7.4%-1.0%6.0%13.4%14.4%11.3%7.3%-12.3%-12.3%
Oncology Portfolio — International net revenues ($M)($M)2
714749667652650606589574597576538539
Oncology Portfolio — International reported growth YoY (%)(%)
9.9%23.4%13.6%13.4%8.7%5.4%9.4%6.5%9.3%12.1%2.9%-0.4%
Oncology Portfolio — International operational (constant-currency) growth YoY (%)(%)
7.6%15.7%10.8%10.4%8.3%10.0%11.8%10.3%13.8%14.3%2.3%-1.0%
Oncology Portfolio — Worldwide reported growth YoY (%)(%)
-1.5%-0.2%-1.5%-0.3%2.6%5.8%12.0%11.6%10.5%9.0%-7.4%-8.4%
Oncology Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)
-2.4%-3.0%-2.5%-1.3%2.4%7.5%12.9%13.0%12.2%9.8%-7.6%-8.6%
Venclexta (venetoclax) — Worldwide net revenues ($M)($M)4
771770710726691665655677637614589590
Venclexta (venetoclax) — U.S. net revenues ($M)($M)1
369341332341321312313340300281276281
Venclexta (venetoclax) — U.S. reported growth YoY (%)(%)
14.8%9.2%6.2%7.4%11.0%13.0%21.5%12.8%6.2%3.1%8.1%
Venclexta (venetoclax) — International net revenues ($M)($M)2
402429378385370353342337337333313309
Venclexta (venetoclax) — International reported growth YoY (%)(%)
8.8%21.4%10.8%14.3%9.5%6.0%9.3%8.9%10.4%21.9%26.4%21.1%
Venclexta (venetoclax) — International operational (constant-currency) growth YoY (%)(%)
5.0%10.1%6.6%10.0%9.1%13.4%13.2%15.4%18.4%26.1%25.1%19.9%
Venclexta (venetoclax) — Worldwide reported growth YoY (%)(%)
11.6%15.7%8.6%7.1%8.5%8.3%11.0%14.8%11.5%14.2%14.3%14.6%
Venclexta (venetoclax) — Worldwide operational (constant-currency) growth YoY (%)(%)
9.6%9.7%6.4%4.9%8.3%12.3%13.0%18.2%15.8%16.3%13.7%14.0%
Imbruvica (ibrutinib) — Worldwide net revenues ($M)($M)4
532556671706754738848828833838903908
Imbruvica (ibrutinib) — U.S. net revenues ($M)($M)1
337332469507543529625618595610683678
Imbruvica (ibrutinib) — U.S. reported growth YoY (%)(%)
-37.8%-37.4%-25.0%-17.9%-8.9%-13.3%-8.6%-8.9%-10.6%-4.3%-18.6%-20.2%
Imbruvica (ibrutinib) — International net revenues ($M)($M)2
195224202199211209223210238228220230
Imbruvica (ibrutinib) — International reported growth YoY (%)(%)
-7.8%7.2%-9.0%-5.8%-11.2%-8.2%1.2%-8.4%-1.4%-5.1%-20.0%-19.6%
Imbruvica (ibrutinib) — International operational (constant-currency) growth YoY (%)(%)
-7.8%7.2%-9.0%-5.8%-11.2%-8.2%1.2%-8.4%-1.4%-5.1%-20.0%-19.6%
Imbruvica (ibrutinib) — Worldwide reported growth YoY (%)(%)
-29.4%-24.7%-20.8%-14.8%-9.5%-11.9%-6.2%-8.8%-8.2%-4.5%-19.0%-20.0%
Imbruvica (ibrutinib) — Worldwide operational (constant-currency) growth YoY (%)(%)
-29.4%-24.7%-20.8%-14.8%-9.5%-11.9%-6.2%-8.8%-8.2%-4.5%-19.0%-20.0%
Elahere (mirvetuximab soravtansine) — Worldwide net revenues ($M)($M)4
21119818217015917914813912864
Elahere (mirvetuximab soravtansine) — U.S. net revenues ($M)($M)1
1611601541501381651461391286400
Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%)(%)
17.1%-2.9%5.0%8.6%8.0%
Elahere (mirvetuximab soravtansine) — International net revenues ($M)($M)
5038282021142000
Elahere (mirvetuximab soravtansine) — Worldwide reported growth YoY (%)(%)
33.1%10.7%22.6%23.3%24.2%
Elahere (mirvetuximab soravtansine) — Worldwide operational (constant-currency) growth YoY (%)(%)
31.8%8.3%21.3%22.4%23.7%
Epkinly (epcoritamab) — Worldwide net revenues ($M)($M)2
1038381697051404336271714
Epkinly (epcoritamab) — U.S. net revenues ($M)($M)1
645152444936363129221414
Epkinly (epcoritamab) — U.S. reported growth YoY (%)(%)
62.4%22.1%23.8%30.8%57.4%66.7%48.9%13.4%
Epkinly (epcoritamab) — International net revenues ($M)($M)
3932292521154127530
Other Oncology — Worldwide net revenues ($M)($M)1
3324201120000
Other Oncology — U.S. net revenues ($M)($M)
3324201120000
Aesthetics Portfolio — Worldwide net revenues ($M)($M)7
1,2821,1861,2861,1931,2791,1021,2981,2391,3901,2491,3711,239
Aesthetics Portfolio — U.S. net revenues ($M)($M)1
761704811742797640839791863776884759
Aesthetics Portfolio — U.S. reported growth YoY (%)(%)
-4.4%9.8%-3.3%-6.2%-7.8%-17.4%-5.0%3.9%4.4%-0.3%5.7%
Aesthetics Portfolio — International net revenues ($M)($M)2
521482475451482462459448527473487480
Aesthetics Portfolio — International reported growth YoY (%)(%)
8.1%4.5%3.3%0.8%-8.5%-2.4%-5.6%-6.4%-5.4%-9.4%7.6%-11.4%
Aesthetics Portfolio — International operational (constant-currency) growth YoY (%)(%)
5.0%-1.5%2.5%-0.6%-8.3%1.6%-3.2%-1.6%0.4%-5.5%9.0%-9.7%
Aesthetics Portfolio — Worldwide reported growth YoY (%)(%)
0.3%7.6%-0.9%-3.7%-8.1%-11.7%-5.2%-0.1%0.5%-4.0%6.4%-4.7%
Aesthetics Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)
-0.9%5.1%-1.2%-4.2%-8.0%-10.2%-4.4%1.8%2.8%-2.5%6.9%-4.0%
Botox Cosmetic (onabotulinumtoxinA) — Worldwide net revenues ($M)($M)4
728668717637692556687671729633718620
Botox Cosmetic (onabotulinumtoxinA) — U.S. net revenues ($M)($M)1
400371420379410295429414450389453388
Botox Cosmetic (onabotulinumtoxinA) — U.S. reported growth YoY (%)(%)
-2.4%25.8%-2.1%-8.4%-8.7%-24.3%-5.2%6.5%7.1%-4.9%7.3%5.0%
Botox Cosmetic (onabotulinumtoxinA) — International net revenues ($M)($M)2
328297297258282261258257279244265232
Botox Cosmetic (onabotulinumtoxinA) — International reported growth YoY (%)(%)
16.4%13.9%14.7%0.7%0.9%6.9%-2.5%10.9%5.2%-2.2%20.6%-13.3%
Botox Cosmetic (onabotulinumtoxinA) — International operational (constant-currency) growth YoY (%)(%)
12.1%7.1%13.5%-0.6%1.2%11.1%-0.3%15.5%10.9%1.2%22.0%-10.9%
Botox Cosmetic (onabotulinumtoxinA) — Worldwide reported growth YoY (%)(%)
5.2%20.2%4.2%-4.9%-5.0%-12.3%-4.2%8.2%6.4%-3.9%11.8%-2.7%
Botox Cosmetic (onabotulinumtoxinA) — Worldwide operational (constant-currency) growth YoY (%)(%)
3.4%17.0%3.8%-5.4%-4.9%-10.7%-3.4%9.9%8.6%-2.6%12.3%-1.7%
Juvederm Collection — Worldwide net revenues ($M)($M)4
245232249253260231279258343297334321
Juvederm Collection — U.S. net revenues ($M)($M)1
103851079810575120105138106156116
Juvederm Collection — U.S. reported growth YoY (%)(%)
-2.0%12.2%-11.0%-7.5%-23.6%-29.0%-22.5%-10.2%10.4%-13.2%20.5%-6.4%
Juvederm Collection — International net revenues ($M)($M)2
142147142155155156159153205191178205
Juvederm Collection — International reported growth YoY (%)(%)
-8.6%-5.3%-10.5%1.4%-24.4%-18.5%-10.9%-25.1%-15.6%-18.1%-8.0%-9.8%
Juvederm Collection — International operational (constant-currency) growth YoY (%)(%)
-9.7%-10.3%-10.7%-0.2%-24.4%-15.0%-8.7%-20.8%-10.0%-14.0%-7.3%-8.7%
Juvederm Collection — Worldwide reported growth YoY (%)(%)
-6.0%0.4%-10.7%-2.2%-24.0%-22.2%-16.3%-19.7%-6.8%-16.4%3.4%-8.6%
Juvederm Collection — Worldwide operational (constant-currency) growth YoY (%)(%)
-6.6%-2.9%-10.8%-3.2%-24.0%-20.0%-15.1%-16.9%-3.1%-13.7%3.8%-7.9%
Other Aesthetics — Worldwide net revenues ($M)($M)4
309286320303327315332310318319319298
Other Aesthetics — U.S. net revenues ($M)($M)1
258248284265282270290272275281275255
Other Aesthetics — U.S. reported growth YoY (%)(%)
-8.3%-8.4%-1.8%-2.3%1.6%-3.5%5.2%6.4%-2.3%13.7%-3.3%-4.0%
Other Aesthetics — International net revenues ($M)($M)2
513836384545423843384443
Other Aesthetics — International reported growth YoY (%)(%)
14.1%-15.7%-14.5%-0.8%5.8%18.1%-2.3%-10.0%-11.7%-3.7%12.6%-8.1%
Other Aesthetics — International operational (constant-currency) growth YoY (%)(%)
11.8%-20.5%-15.0%-2.2%6.4%23.2%1.5%-2.0%-4.1%1.2%16.9%-7.0%
Other Aesthetics — Worldwide reported growth YoY (%)(%)
-5.2%-9.4%-3.4%-2.1%2.2%-0.9%4.2%4.0%-3.6%11.3%-1.5%-4.6%
Other Aesthetics — Worldwide operational (constant-currency) growth YoY (%)(%)
-5.5%-10.1%-3.5%-2.3%2.3%-0.3%4.7%5.1%-2.5%12.0%-1.0%-4.4%
Other Key Products Portfolio — Worldwide net revenues ($M)($M)7
9359958841,0061,037809912874962900968963
Other Key Products Portfolio — U.S. net revenues ($M)($M)1
761816711829835636748710750686778751
Other Key Products Portfolio — U.S. reported growth YoY (%)(%)
-9.1%28.5%-5.1%16.9%11.2%-7.2%-3.8%-5.6%0.9%-5.6%-1.5%-4.6%
Other Key Products Portfolio — International net revenues ($M)($M)2
174179173177202173164164212214190212
Other Key Products Portfolio — International reported growth YoY (%)(%)
-13.4%3.0%5.3%8.1%-4.4%-19.4%-14.1%-22.1%4.1%6.3%-2.3%4.4%
Other Key Products Portfolio — International operational (constant-currency) growth YoY (%)(%)
-15.5%-7.9%1.3%3.4%-5.8%-14.8%-13.9%-19.5%8.8%8.8%-1.0%4.9%
Other Key Products Portfolio — Worldwide reported growth YoY (%)(%)
-9.9%23.0%-3.2%15.2%7.8%-10.1%-5.8%-9.3%1.6%-3.0%-1.7%-2.8%
Other Key Products Portfolio — Worldwide operational (constant-currency) growth YoY (%)(%)
-10.3%20.7%-3.9%14.3%7.5%-9.0%-5.8%-8.7%2.6%-2.4%-1.4%-2.7%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide net revenues ($M)($M)4
295351324312375306291302369349309370
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. net revenues ($M)($M)1
133183163146184142137147167144128167
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. reported growth YoY (%)(%)
-27.7%28.3%17.9%-0.2%9.7%-0.7%7.8%-12.7%-13.2%-15.8%-33.5%-12.3%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International net revenues ($M)($M)2
162168161166191164154155202205181203
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International reported growth YoY (%)(%)
-14.9%2.4%4.9%6.9%-5.1%-20.4%-15.4%-23.1%3.8%6.2%-3.0%5.2%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International operational (constant-currency) growth YoY (%)(%)
-16.9%-8.6%0.8%2.1%-6.5%-15.8%-15.1%-20.5%8.8%9.0%-1.5%5.8%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide reported growth YoY (%)(%)
-21.2%14.5%11.0%3.5%1.6%-12.3%-5.8%-18.4%-4.7%-4.1%-18.5%-3.5%
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide operational (constant-currency) growth YoY (%)(%)
-22.2%8.6%8.9%1.0%0.8%-9.6%-5.6%-17.0%-2.2%-2.6%-17.8%-3.2%
Creon (pancrelipase) — Worldwide net revenues ($M)($M)3
345361385368404355388338372285376305
Creon (pancrelipase) — U.S. net revenues ($M)($M)1
345361385368404355388338372285376305
Creon (pancrelipase) — U.S. reported growth YoY (%)(%)
-14.7%1.8%-0.8%9.1%8.4%24.6%3.3%10.6%32.1%-6.6%11.5%-9.1%
Creon (pancrelipase) — Worldwide reported growth YoY (%)(%)
-14.7%1.8%-0.8%9.1%8.4%24.6%3.3%10.6%32.1%-6.6%11.5%-9.1%
Creon (pancrelipase) — Worldwide operational (constant-currency) growth YoY (%)(%)
-14.7%1.8%-0.8%9.1%8.4%24.6%3.3%10.6%32.1%-6.6%11.5%-9.1%
Linzess/Constella (linaclotide) — Worldwide net revenues ($M)($M)2
295283175326258148233234221266283288
Linzess/Constella (linaclotide) — U.S. net revenues ($M)($M)
283272163315247139223225211257274279
Linzess/Constella (linaclotide) — International net revenues ($M)($M)
1211121111910910999
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M)($M)9
580509514506646525533538585605
Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. net revenues ($M)($M)1
286221226221358240239227314310
Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. reported growth YoY (%)(%)
-19.7%-8.0%-5.7%-2.6%12.8%-22.9%-21.8%-29.2%-6.9%-14.0%
Eye Care Portfolio [folded into All Other in Q1 2026] — International net revenues ($M)($M)2
294288288285288285294311271295
Eye Care Portfolio [folded into All Other in Q1 2026] — International reported growth YoY (%)(%)
1.6%1.3%-2.4%-8.0%7.3%-3.5%-4.7%7.6%7.2%13.1%
Eye Care Portfolio [folded into All Other in Q1 2026] — International operational (constant-currency) growth YoY (%)(%)
-0.4%-1.0%-1.5%-2.0%9.8%1.2%0.2%10.3%6.7%13.9%
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%)(%)
-10.1%-3.0%-3.9%-5.7%10.2%-13.5%-13.3%-11.7%-0.9%-2.7%
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)(%)
-11.0%-4.2%-3.4%-2.2%11.4%-11.2%-10.9%-10.4%-1.1%-2.4%
Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M)($M)4
128117125123120119124131118120
Ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M)($M)1
32323030363335343634
Ozurdex (dexamethasone intravitreal implant) — U.S. reported growth YoY (%)(%)
-10.4%-4.9%-12.6%-12.1%-3.2%-2.3%4.2%-13.7%3.0%-4.5%
Ozurdex (dexamethasone intravitreal implant) — International net revenues ($M)($M)2
96859593848689978286
Ozurdex (dexamethasone intravitreal implant) — International reported growth YoY (%)(%)
14.1%-0.3%5.8%-3.8%3.0%-0.3%4.6%27.9%17.0%22.3%
Ozurdex (dexamethasone intravitreal implant) — International operational (constant-currency) growth YoY (%)(%)
10.4%-3.6%4.4%1.1%3.5%2.5%9.5%29.3%15.4%21.7%
Ozurdex (dexamethasone intravitreal implant) — Worldwide reported growth YoY (%)(%)
6.9%-1.6%0.6%-6.0%1.1%-0.9%4.5%13.7%12.3%13.2%
Ozurdex (dexamethasone intravitreal implant) — Worldwide operational (constant-currency) growth YoY (%)(%)
4.3%-4.0%-0.4%-2.4%1.4%1.1%8.0%14.6%11.3%12.8%
Lumigan/Ganfort (bimatoprost) — Worldwide net revenues ($M)($M)4
10497103106119116103919291
Lumigan/Ganfort (bimatoprost) — U.S. net revenues ($M)($M)1
47425248585842293128
Lumigan/Ganfort (bimatoprost) — U.S. reported growth YoY (%)(%)
-19.0%-26.1%19.9%69.2%83.9%-15.8%-55.0%-44.1%-53.0%
Lumigan/Ganfort (bimatoprost) — International net revenues ($M)($M)2
57555158615861626163
Lumigan/Ganfort (bimatoprost) — International reported growth YoY (%)(%)
-6.6%-6.0%-15.4%-6.8%0.9%-7.0%-11.2%-7.6%-9.9%2.7%
Lumigan/Ganfort (bimatoprost) — International operational (constant-currency) growth YoY (%)(%)
-9.1%-8.7%-15.2%-0.5%2.2%-2.7%-8.1%-6.4%-11.9%1.4%
Lumigan/Ganfort (bimatoprost) — Worldwide reported growth YoY (%)(%)
-12.6%-15.9%-0.8%17.0%29.4%27.2%-13.2%-30.5%-25.5%-24.8%
Lumigan/Ganfort (bimatoprost) — Worldwide operational (constant-currency) growth YoY (%)(%)
-13.9%-17.3%-0.7%21.4%30.2%30.2%-11.4%-29.9%-26.6%-25.5%
Alphagan/Combigan (brimonidine) — Worldwide net revenues ($M)($M)4
54473660786249596670
Alphagan/Combigan (brimonidine) — U.S. net revenues ($M)($M)1
189026412613153130
Alphagan/Combigan (brimonidine) — U.S. reported growth YoY (%)(%)
-54.8%-67.4%-91.6%68.5%33.6%-15.3%-59.5%-47.0%-26.8%-16.0%
Alphagan/Combigan (brimonidine) — International net revenues ($M)($M)2
36383634373636443540
Alphagan/Combigan (brimonidine) — International reported growth YoY (%)(%)
-4.5%6.8%-3.1%-21.4%6.8%-10.0%9.1%1.9%7.2%10.1%
Alphagan/Combigan (brimonidine) — International operational (constant-currency) growth YoY (%)(%)
-5.4%4.7%-0.2%-15.4%10.2%-4.5%20.5%6.9%9.8%17.3%
Alphagan/Combigan (brimonidine) — Worldwide reported growth YoY (%)(%)
-30.5%-24.7%-25.6%1.9%19.2%-12.3%-23.7%-17.7%-11.7%-3.1%
Alphagan/Combigan (brimonidine) — Worldwide operational (constant-currency) growth YoY (%)(%)
-30.9%-25.9%-23.5%6.3%21.0%-9.2%-17.8%-14.7%-10.5%0.4%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M)($M)4
114213257128117
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. net revenues ($M)($M)1
10281844117104
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%)(%)
-13.7%-92.5%-77.3%-44.1%13.5%-20.7%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International net revenues ($M)($M)2
121314131113
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International reported growth YoY (%)(%)
14.9%2.1%-18.9%-1.4%44.7%35.0%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International operational (constant-currency) growth YoY (%)(%)
19.7%8.1%-14.5%4.1%51.4%42.1%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide reported growth YoY (%)(%)
-11.3%-82.2%-67.0%-38.1%15.6%-17.0%
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide operational (constant-currency) growth YoY (%)(%)
-10.9%-81.5%-66.2%-37.3%16.1%-16.5%
Other Eye Care — Worldwide net revenues ($M)($M)4
294248250217329228257257617207
Other Eye Care — U.S. net revenues ($M)($M)1
189138144117223123149149481114
Other Eye Care — U.S. reported growth YoY (%)(%)
-14.9%12.3%-4.3%-21.4%20.9%1.7%18.9%-4.8%-2.5%16.3%
Other Eye Care — International net revenues ($M)($M)2
10511010610010610510810813693
Other Eye Care — International reported growth YoY (%)(%)
-1.5%4.7%-1.7%-7.1%15.4%-2.0%-10.1%5.9%9.7%11.9%
Other Eye Care — International operational (constant-currency) growth YoY (%)(%)
-2.3%3.5%0.9%-0.2%20.3%4.2%-6.1%9.3%9.3%12.0%
Other Eye Care — Worldwide reported growth YoY (%)(%)
-10.5%8.8%-3.2%-15.4%18.4%4.8%2.6%14.2%
Other Eye Care — Worldwide operational (constant-currency) growth YoY (%)(%)
-10.8%8.2%-2.1%-12.5%20.6%2.8%6.7%1.5%2.4%14.2%
Research and Development (R&D) Expense — GAAP ($M)($M)3
2,3442,4722,5792,3192,1312,0676,7742,1301,9481,9391,9271,723
Adjusted R&D Expense — Non-GAAP ($M)($M)
2,3142,26818.32,2562,11514.220.22,0551,91714.817.215.7
GAAP R&D Expense % of Net Revenues (%)(%)
13.8%16.5%15.5%14.7%13.8%15.5%44.9%14.7%13.5%15.8%
Adjusted R&D Expense % of Net Revenues — Non-GAAP (%)(%)
13.6%15.1%15.4%14.3%13.7%15.4%15.1%14.2%13.3%14.7%
Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M)($M)3
291744-3,1492,680823248-208829371648666
Development and Regulatory Milestones Recognized in R&D ($M)($M)
146412365118235010859622
Acquired IPR&D and Milestones % of Net Revenues (%)(%)
1.7%5.0%7.6%17.0%5.3%1.9%10.4%0.6%6.5%1.3%2.0%0.5%
Acquired IPR&D and Milestones Unfavorable Impact to Diluted EPS ($/sh)($)
0.170.410.711.500.420.130.880.040.520.080.150.04
Janssen Biotech Collaboration (Imbruvica) — International Profit Share in Net Revenues ($M)($M)1
195224202199211209223210238228220230
Janssen U.S. Profit Share Recorded in AbbVie Cost of Products Sold ($M)($M)
157153219235253247291282284283320316
Genentech Collaboration (Venclexta) — Profit Share & Royalties in Cost of Products Sold ($M)($M)
298284274286262242257263243227228225
Adjusted Gross Margin Ratio — Non-GAAP (%)(%)1
84.7%83.6%83.6%83.9%84.4%84.1%83.8%84.4%85.2%82.9%83.9%83.5%
GAAP Gross Margin Ratio (%)(%)
74.7%71.9%72.6%66.4%71.8%70.0%70.9%70.9%70.9%66.7%60.1%53.4%
Adjusted Operating Margin Ratio — Non-GAAP (%)(%)1
48.3%40.8%38.3%30.9%44.3%42.3%34.7%46.7%42.6%42.2%43.8%46.7%
GAAP Operating Margin Ratio (%)(%)
37.9%26.6%27.3%12.1%31.7%28.0%26.5%27.6%22.7%22.3%16.4%
Adjusted SG&A Expense % of Net Revenues — Non-GAAP (%)(%)1
21.0%22.7%22.3%21.6%21.0%24.6%23.6%23.0%22.9%24.6%24.7%23.9%
GAAP SG&A Expense % of Net Revenues (%)(%)
21.4%23.9%23.4%22.6%21.1%24.7%25.5%29.1%23.3%26.9%22.3%24.2%
Adjusted Effective Tax Rate — Non-GAAP (%)(%)2
14.7%15.4%18.3%24.5%16.2%14.2%20.2%16.2%18.8%14.8%17.2%15.7%
GAAP Effective Tax Rate (%)(%)
15.5%32.9%32.0%73.7%39.4%22.4%99.0%25.0%36.0%21.8%32.1%8.8%
Effective Tax Rate on Specified Items (%)(%)
13.7%11.3%7.0%14.9%8.6%10.3%45.4%11.9%8.7%10.8%13.4%18.9%
Adjusted After-Tax Earnings — Non-GAAP ($M)($M)6
6,4914,7114,8303,3065,2784,3703,8445,3274,7104,1204,9595,250
Reported After-Tax Earnings — GAAP ($M)($M)
3,6136951,8161869381,286-221,5611,3701,3698221,778
Adjusted Pre-Tax Earnings — Non-GAAP ($M)($M)
7,6135,5695,9094,3806,3045,0994,8136,3575,8044,8385,9906,233
Reported Pre-Tax Earnings — GAAP ($M)($M)
4,2781,0392,6687141,5541,661-2,2692,0842,1461,7551,2121,953
Adjusted Cost of Products Sold — Non-GAAP ($M)($M)
2,5982,4625,9092,5472,4135,0994,8132,2512,1354,8385,9906,233
Adjusted SG&A Expense — Non-GAAP ($M)($M)
3,5743,4011,0803,4123,2397269703,3263,3157151,029980
Adjusted Income Tax Expense — Non-GAAP ($M)($M)
1,1198561,0801,0721,0237269701,0271,0917151,029980
Adjusted Diluted Earnings Per Share — Non-GAAP ($/sh)($)5
3.652.652.711.862.972.462.1632.652.312.792.95
Reported Diluted Earnings Per Share — GAAP ($/sh)($)
2.030.391.020.100.520.72-0.020.880.770.770.461
Total Specified Items — Pre-Tax ($M)($M)
3,3354,5303,2413,6664,7503,4387,0824,2733,6583,0834,7784,280
Total Specified Items — Income Tax Impact ($M)($M)
4575142275464103543,216507318332641808
Specified Item: Intangible Asset Amortization — Pre-Tax ($M)($M)2
1,6891,7481,7841,8711,8641,8581,8961,8881,9471,8911,8892,039
Intangible Asset Amortization — After-Tax ($M)($M)
1,4361,4981,5001,5761,5711,5741,6071,6001,6511,6031,5841,728
Intangible Asset Amortization — Diluted EPS Impact ($/sh)($)
0.810.850.850.890.890.890.900.890.930.900.890.98
Specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M)($M)2
1,5182,3871,4067762,7951,5182791,3561,4766601,6968
Change in Fair Value of Contingent Consideration — After-Tax ($M)($M)
1,4792,3251,3687552,7091,4772711,3211,4386431,6558
Change in Fair Value of Contingent Consideration — Diluted EPS Impact ($/sh)($)
0.831.310.770.431.530.830.150.750.810.360.93
Contingent Consideration Liability — Total Level 3 Fair Value ($M)($M)8
27,49527,03925,37424,64924,64922,71321,66621,92621,15020,15919,89018,674
Level 3 Rollforward — Additions ($M)($M)
00000780000
Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M)($M)
1,5182,3871,4067762,7951,5182791,3561,4766601,6968
Level 3 Rollforward — Cash Settlements and Payments ($M)($M)1
1,062722681776859549539580485391480485
Contingent Consideration Payments — Operating Cash Flow Portion ($M)($M)
1,062722681776859549539580485391463391
Valuation Inputs — Discount Rate Minimum (%)(%)
4.2%4.1%4.8%3.8%4.0%4.2%4.6%3.9%4.8%4.6%4.3%5.3%
Valuation Inputs — Discount Rate Maximum (%)(%)
5.5%5.0%3.7%4.6%4.8%4.9%5.2%5.1%5.9%5.8%5.9%6.1%
Valuation Inputs — Discount Rate Weighted Average (%)(%)
4.5%4.3%4.0%4.1%4.3%4.5%4.8%4.1%5.0%4.8%4.5%5.5%
Valuation Inputs — Payment Probability Maximum (%)(%)
100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Valuation Inputs — Payment Probability Weighted Average (%)(%)
93.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%99.0%99.0%99.0%
Recorded Litigation Accrual Reserve ($M)($M)4
1,7001,7001,6001,5001,8001,8002,5002,4002,000
Net Litigation Reserve Charges / Adjustments ($M)($M)
-64150136-319-21-72916731439-12-238-87
Pending Legal Claims — Prescription Opioid Lawsuits Total (cases)2
215320335380380430435440460580590610
Pending Claims — Prescription Opioid State Lawsuits (cases)
202025252530353545165175160
Pending Claims — Prescription Opioid Municipal & Local Lawsuits (cases)
2020202020252530
Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases)
4757575757575757575
Pending Legal Claims — Other Product Liability Lawsuits (cases)1
1,3001,3201,3201,3001,2901,2601,1001,0001,000
Pending Claims — International Product Liability Lawsuits (cases)
1,0801,0801,0801,0251,0051,0001,000800800
Inventories, Net ($M)($M)3
5,1275,0494,9514,9384,9604,5264,1814,4504,2184,2454,0993,981
Finished Goods ($M)($M)
1,6711,8061,5801,5791,6811,4411,1731,3471,1891,2581,3561,035
Work in Process ($M)($M)
2,3162,1372,2872,2772,1131,9741,9512,0711,9301,8901,6431,690
Raw Materials ($M)($M)
1,1401,1061,0841,0821,1661,1111,0571,0321,0991,0971,1001,256
Property, Plant and Equipment, Net ($M)($M)4
5,7965,6875,6285,4835,2835,2375,1345,1415,0234,9804,9894,934
Property, Plant and Equipment, Gross ($M)($M)
13,95513,73113,53013,22912,93412,57112,26712,27911,90311,72511,63511,374
Accumulated Depreciation ($M)($M)
8,1598,0447,9027,7467,6517,3347,1337,1386,8806,7456,6466,440
Depreciation Expense ($M)($M)
194188203192186181206191184183187196
Capital Expenditures ($M)($M)
322265329381269235291249241193205219
Intangible Assets, Net ($M)($M)4
49,13950,87352,64154,31557,03158,48960,06866,64660,24362,22555,61058,603
Goodwill ($M)($M)
35,51935,57035,64035,62635,63835,28534,95635,29533,38633,42632,29332,091
Definite-Lived Intangible Assets, Net ($M)($M)4
44,73845,60147,36049,03451,74553,19854,86656,95158,66360,64555,30758,318
Developed Product Rights, Net ($M)($M)2
44,07744,78546,39047,87450,39651,65753,17554,99856,44658,16052,68755,356
Developed Product Rights, Gross ($M)($M)
81,96881,16581,23981,12682,15081,63881,42881,72181,49782,21975,14276,526
Developed Product Rights, Accumulated Amortization ($M)($M)
37,89136,38034,84933,25231,75429,98128,25326,72325,05124,05922,45521,170
License Agreements, Net ($M)($M)2
6618169701,1601,3491,5411,6911,9532,2172,4852,6202,962
License Agreements, Gross ($M)($M)
8,3598,3598,3538,3538,3528,3528,3158,3168,3158,3168,1918,261
License Agreements, Accumulated Amortization ($M)($M)
7,6987,5437,3837,1937,0036,8116,6246,3636,0985,8315,5715,299
Definite-Lived Intangible Assets, Gross ($M)($M)
90,32789,52489,59289,47990,50289,99089,74390,03789,81290,53583,33384,787
Definite-Lived Intangible Assets, Accumulated Amortization ($M)($M)
45,58943,92342,23240,44538,75736,79234,87733,08631,14929,89028,02626,469
Indefinite-Lived IPR&D Intangible Assets ($M)($M)
4,4015,2725,2815,2815,2865,2915,2029,6951,5801,580303285
Intangible Asset Amortization Expense ($M)($M)
1,7001,7001,8001,9001,9001,9001,9001,9001,9001,9001,8002,000
Long-Term Debt and Finance Lease Obligations, Noncurrent ($M)($M)2
62,48164,53258,94162,97162,95964,52760,34058,50958,04863,80552,19455,631
Current Portion of Long-Term Debt and Finance Leases ($M)($M)
8,3418,3266,0561,9821,9663,7696,80412,57012,58610,1937,1915,113
Short-Term Borrowings ($M)($M)
002,4993,7905,5561,5930302
Cash Dividends Declared ($M)($M)6
3,0743,0743,0752,9172,9142,9132,9142,7572,7542,7532,7552,634
Dividends Declared per Common Share ($/sh)($)
1.731.731.731.641.641.641.641.551.551.551.551.48
Cash Paid for Purchases of Common Stock ($M)($M)
91,48934129613581791,32434
Common Stock Held in Treasury (M shares)
77.1077.1070.8070.8070.8070.8066.3064.3064.3064.2057.1057.10
Treasury Stock Carrying Value ($M)($M)
10,61810,6119,1469,1439,1479,1378,2017,8487,8387,8296,5336,525
Stock-Based Compensation Expense ($M)($M)
166444157209179410164181218348125130
Stock-Based Compensation Tax Benefit ($M)($M)
297531353470323334602526
Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) [year-end] ($M)4
Net Periodic Pension Benefit Cost ($M)($M)
-14-31-14-13-6-201111-1-1
Pension Service Cost ($M)($M)
686367666863727171726768
Pension Interest Cost ($M)($M)
128122121122124117112113113113108108
Expected Return on Pension Plan Assets ($M)($M)
222224209209208206196196196197180181
Other Post-Employment Benefit (OPEB) Plans — Benefit Obligation [year-end] ($M)3
Net Periodic OPEB Cost ($M)($M)
131515151414161617161312
OPEB Service Cost ($M)($M)
10111010101011111011109
OPEB Interest Cost ($M)($M)
1011111111111010111099
Income Tax Expense ($M)($M)1
662342853526613372-2,246520773383388172
Deferred Income Tax Expense (Benefit) ($M)($M)
-195137-385193-272-28-767-277-16-389-1,391-863
PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100)
926.70925.40919.10917.40915.10915.30918.10917.30914.40907.80896.30896.50
U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M)($M)1
97,48195,519103,201102,234100,19098,46797,36595,99289,71687,92789,67385,816
U.S. Retail Sales: Pharmacies and Drug Stores — Not Seasonally Adjusted ($M)($M)
97,05993,047106,419102,17199,81895,892100,31295,79289,17386,98791,91485,089
Income Statement — Net revenues ($M)($M)14
16,99015,00216,61815,77615,42313,34315,10214,46014,46212,31014,30113,927
Cost of products sold ($M)($M)
4,2914,2184,5525,3044,3464,0024,3964,2124,2024,0945,7046,485
Total operating costs and expenses ($M)($M)
10,55811,01212,07413,87210,5299,61016,59210,62910,4649,51211,10611,646
Selling, general and administrative expense ($M)($M)
3,6323,5783,8953,5693,2533,2933,8554,2053,3773,3153,1933,372
Research and development expense ($M)($M)
2,3442,4722,5792,3192,1312,0676,7742,1301,9481,9391,9271,723
Operating earnings ($M)($M)
6,4323,9904,5441,9044,8943,733-1,4903,8313,9982,7983,1952,281
Interest expense ($M)($M)
746717714739740700702720726660564555
Interest income ($M)($M)
67725972627392129220207186157
Earnings before income tax ($M)($M)
4,2781,0392,6687141,5541,661-2,2692,0842,1461,7551,2121,953
Income tax expense ($M)($M)
662342853526613372-2,246520773383388172
Net earnings attributable to AbbVie Inc. ($M)($M)
3,6016851,8061769281,276-321,5511,3601,3598111,767
Earnings per share — Basic ($/sh)($)
2.040.391.020.100.520.72-0.020.880.770.770.461
Earnings per share — Diluted ($/sh)($)
2.030.391.020.100.520.72-0.020.880.770.770.461
Weighted-average basic shares outstanding (M)
1,769.001,770.001,769.001,768.001,768.001,769.001,768.001,769.001,767.00
Weighted-average diluted shares outstanding (M)
1,771.001,774.001,772.001,771.001,772.001,772.001,771.001,773.001,771.00
Balance Sheet — Total assets ($M)($M)12
135,115136,463133,960133,898137,182136,165135,161143,422141,937148,874134,711136,221
Cash and equivalents ($M)($M)
6,5699,3915,2295,6296,4675,1755,5247,25713,13018,06712,81413,287
Accounts receivable, net ($M)($M)
13,82412,47912,58912,76912,63712,47710,91911,47211,72411,94911,15511,412
Inventories ($M)($M)
5,1275,0494,9514,9384,9604,5264,1814,4504,2184,2454,0993,981
Total current assets ($M)($M)
33,66933,52929,06228,53929,26127,67525,58227,78533,81638,87133,00233,224
Property and equipment, net ($M)($M)
5,7965,6875,6285,4835,2835,2375,1345,1415,0234,9804,9894,934
Goodwill ($M)($M)
35,51935,57035,64035,62635,63835,28534,95635,29533,38633,42632,29332,091
Intangible assets, net ($M)($M)
49,13950,87352,64154,31557,03158,48960,06866,64660,24362,22555,61058,603
Accounts payable ($M)($M)
33,30133,77434,73433,61932,24531,0412,94530,49229,32931,3263,68829,658
Total current liabilities ($M)($M)
41,64242,10043,28939,39139,76736,40338,74943,06241,91541,52237,84134,773
Long-term debt and finance lease obligations ($M)($M)
62,48164,53258,94162,97162,95964,52760,34058,50958,04863,80552,19455,631
Retained earnings ($M)($M)
-17,333-17,872-15,493-14,234-11,503-9,527-7,900-4,964-3,768-2,384-1,000933
Total stockholders' equity (deficit) ($M)($M)
-5,888-6,612-3,228-2,599-1381,4623,3646,0716,8218,04710,39712,129
Cash Flow Statement — Operating cash flow ($M)($M)3
3,4363,8295,2187,0245,1531,6357,0485,4472,2714,0404,7537,574
Capital expenditures ($M)($M)
322265329381269235291249241193205219
Cash dividends paid ($M)($M)
3,0703,0862,9112,9112,9102,9252,7522,7512,7502,7722,6262,627
Purchases of common stock ($M)($M)
91,48934129613581791,32434

74 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: AbbVie Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). AbbVie operates as a single global biopharmaceutical operating segment (Note 16), so commercial performance is tracked through Therapeutic Area portfolios and brand-level Worldwide / U.S. / International net revenues.
  • Core commercial & R&D KPIs (Groups 1–8) cover: (1) Consolidated Net Revenues ($17,264M in Q2 2026 / $61,160M in FY25 across U.S. $13,074M and International $4,190M in Q2 2026; +12.0% reported / +11.4% operational YoY), 12-country annual revenue disaggregation (U.S. $47,125M, Germany $1,622M, Japan $1,182M, Canada $1,167M, China $1,111M, France $963M, U.K. $763M, Spain $726M, Italy $650M, Brazil $544M, Australia $447M, Other $4,860M in FY25), and geographic long-lived assets ($11,833M in FY25); (2) Immunology Portfolio ($8,786M in Q2 2026 / $30,406M in FY25, +16.9% reported / +16.4% operational in Q2 2026: Skyrizi $5,505M, Rinvoq $2,525M, Humira $756M); (3) Neuroscience Portfolio ($3,228M in Q2 2026 / $10,767M in FY25, +20.3% reported / +19.8% operational: Vraylar $1,071M, Botox Therapeutic $1,042M, Ubrelvy $392M, Qulipta $350M, Vyalev $256M, Other Neuroscience $117M, plus Duodopa through Q4 2025); (4) Oncology Portfolio ($1,650M in Q2 2026 / $6,655M in FY25: Venclexta $771M, Imbruvica $532M, Elahere $211M, Epkinly $103M, Other Oncology $33M); (5) Aesthetics Portfolio ($1,269M in Q2 2026 / $4,854M in FY25: Botox Cosmetic $728M, Juvederm $245M, Other Aesthetics $296M), Other Key Products (Mavyret $319M, Creon $323M, Linzess/Constella $310M, All Other $1,379M in Q2 2026), Eye Care Portfolio ($2,068M in FY25: Ozurdex $497M, Lumigan/Ganfort $436M, Alphagan/Combigan $231M, Other Eye Care $904M; folded into All Other in Q1 2026), and legacy discontinued franchises; (6) Gross-to-Net (GTN) provisions ($44.9B rebates & chargebacks and $3.27B cash discounts in FY25), Accrued Sales Rebates ($17,032M at FY25), 14-year rollforwards of Medicaid/Medicare ($2,115M ending FY25), Managed Care ($13,544M ending FY25) & Wholesaler Chargebacks ($1,373M ending FY25), and U.S. wholesaler AR concentration (85% in FY25); (7) R&D & Acquired IPR&D ($2,356M GAAP / $2,315M Adjusted R&D and $142M upfront + $50M milestone IPR&D in Q2 2026; Janssen Imbruvica & Genentech Venclexta collaboration profit shares); and (8) GAAP vs. Non-GAAP margins (85.1% Adjusted Gross Margin, 48.0% Adjusted Operating Margin, $3.35 Adjusted Diluted EPS in Q2 2026; $10.00 Adjusted Diluted EPS in FY25) and Specified Items.
  • Groups 9–12 cover: (9) Level 3 Contingent Consideration Liabilities ($26,010M at Q2 2026; Skyrizi/Risankizumab additions, fair value changes, cash payments & discount rate / probability valuation inputs), Litigation Accrual Reserve ($1,395M at Q2 2026) and pending legal claims (Opioid, Biocell ALCL, Product Liability, Niaspan); (10) Inventories by stage ($5,112M net at Q2 2026: Finished Goods $1,427M, WIP $2,310M, Raw Materials $1,375M), PP&E by category ($6,456M net at Q2 2026; 272 facilities / 23M sq ft in FY25), Goodwill ($35,610M) & Intangibles ($54,752M net at Q2 2026 with 5-year estimated amortization schedule), and Operating Leases; (11) Debt & 5-year maturity schedule ($60,646M noncurrent long-term debt at Q2 2026), Capital Return ($3,081M dividends declared / $1.73 per share in Q2 2026; treasury stock & SBC), Defined Benefit Pension ($10,031M PBO / $11,226M plan assets / +$1,195M funded status at FY25) & OPEB plans, and Income Taxes (DTA/DTL breakdown & UTB rollforward $2,756M at FY25); and (12) Global Workforce (55,000 employees, 8% turnover, 34% internal hire rate, 6,500 new hires, 55% women globally, 58% women in STEM in FY25), CEO Pay Ratio (251:1 / $133,895 median employee in FY25), Form 11-K AbbVie Savings Plan ($14.80B net assets at FY25), Workplace Safety (0.11 TRIR / 0.04 LTIR in FY25), Product Quality (55 external / 7 FDA inspections in FY25), Form SD 3TG Suppliers (73 suppliers / 86% response rate in FY25), and Scope 1 & 2 GHG Emissions, Energy, Water & Waste.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as '>100.0%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-10-26.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Immunology Portfolio Net Revenues & Operational Growth (Skyrizi, Rinvoq, Humira)

Neuroscience Portfolio Net Revenues & Operational Growth (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev)

Oncology Portfolio Net Revenues & Operational Growth (Venclexta, Imbruvica, Elahere, Epkinly)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của AbbVie

See a number that looks wrong?